- In 2025, we grew revenue by 60% year over year
- Delivered >$55M in revenue while taking serious market share
- Added 4 products to our portfolio (ATLAS, IKON, DBX, Summit Matrix)
- Our grafts are on shelf in facilities across all 50 states
- Kolosis grafts are approved in over 5,800 facilities across the country
- Kolosis bone grafts were utilized in over 35,000 fusion procedures
- We ranked #8 on the Utah Fast 50 for 2025
- We partnered with over 400 active sales reps
Salt Lake City, Utah — Kolosis®, the industry’s leading pure-play surgical biologics company, proudly announces its 2025 results with confidence as it sets its sights on expected 2026 performance.
Kolosis leadership recognizes a year of exceptional growth. “I couldn’t be more excited about our progress,” said Collin Begley, CEO of Kolosis. “With 60% revenue growth and $55M+ in revenue, our momentum continues to build.”


